Krishna Patel, MD
Ophthalmic Plastic and Reconstructive Surgery · Wheaton, ILNPI 1477972412
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,178 of the $3,752 with a category attached, or 84.7%. 13 manufacturers reported payments, led by AbbVie at 26.0% of the total. Reporting peaked in 2023 at $1,141 and has fallen 53.6% since, to $530 in 2025.
Across 58 payments — averaging $64.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$976
- Amgen$865
- Atricure, Inc.$574
- Alcon$261
- Glaukos Corporation$203
- Integra Lifesciences Corporation$144
- plus $729 from 7 others
What the payments were for
- Travel & lodging$57415%
- Food & beverage$3,17885%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $976 |
| Amgen(2 entities) | 21 | $865 |
| Atricure, Inc. | 1 | $574 |
| Alcon | 2 | $261 |
| Glaukos Corporation | 1 | $203 |
| Integra Lifesciences Corporation | 1 | $144 |
| Genentech USA, Inc. | 1 | $141 |
| NEW World Medical,inc. | 1 | $127 |
| Eyepoint US, Inc. | 1 | $125 |
| Sun Pharmaceutical Industries Inc. | 1 | $114 |
| Cook Medical LLC | 1 | $111 |
| Johnson & Johnson | 5 | $89 |
| Abbott | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNERGY ABLATION SYSTEM$574
- ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2)$574
- TEPEZZA$475
- INTEGRA$433
- iDoseTR$203
- iStent Infinite$203
- XEN GLAUCOMA TREATMENT SYSTEM$150
- Clareon$146
- INTEGRA DERMAL REGENERATION TEMPLATE$144
- PRIMATRIX$144
- SUSVIMO$141
- Kahook Dual Blade$127
- Clearpath$127
- Ahmed Glaucoma Valve$127
- Streamline$127
- DEXYCU$125
- Humira$125
- SIMBRINZA$115
- Rocklatan$115
- Rhopressa$115
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 345 | $3,263 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 183 | $1,770 |
| Prednisolone Acetate | 32 | $897 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 120 | $509 |
| MoxifloxacinMoxifloxacin Hcl | 25 | $305 |
| Doxycycline Hyclate | 14 | $140 |
| Tramadol Hcl | 16 | $24 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Wheaton
- John PakWheaton$241
- Tamara FountainDeerfield$1M
- Paul PhelpsChicago$141K
- Kenya WilliamsChicago$23K
- Liza CohenChicago$5K
- Stephen WinklerDes Plaines$3K
- Hassan ShahChicago$1K
- Jamie KeenHines$1K
- Duaa SharfiMerrionette Park$1K
- Olivia ChengChicago$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.